Stephen Welch is the executive vice president and head of Specialty Generics at Mallinckrodt Pharmaceuticals. He has executive responsibility for leading the Specialty Generics business and is a member of Mallinckrodt’s executive committee.
Mr. Welch has more than 20 years of experience in corporate finance and strategy matters, including over 15 years in the pharmaceuticals industry. He’s an established leader with a demonstrated ability to create value, drive results and strengthen culture.
Mr. Welch joined Mallinckrodt in 2012 and has held increasingly strategic roles. Before assuming leadership of the Specialty Generics business in early 2022, he served as the segment’s chief financial officer and was chief transformation officer during the company’s 2020-22 restructuring. Earlier roles included vice president of corporate strategy and chief of staff to the president and chief executive officer. He began his time at Mallinckrodt primarily focused on M&A transactions and business integrations.
Prior to joining Mallinckrodt, Mr. Welch was head of the tax departments at Human Genome Sciences and PharMerica. He began his career at PricewaterhouseCoopers.
Mr. Welch holds a Juris Doctor from the Georgetown University Law Center and a bachelor’s degree in political science from the California State University, Bakersfield. In addition, he completed Harvard Business School’s Advanced Management Program.